Modality
Peptide
MOA
WRNi
Target
SHP2
Pathway
Complement
MMDravet
Development Pipeline
Preclinical
~Mar 2013
→ ~Jun 2014
Phase 1
~Sep 2014
→ ~Dec 2015
Phase 2
~Mar 2016
→ ~Jun 2017
Phase 3
Sep 2017
→ Sep 2031
Phase 3Current
NCT03093432
91 pts·Dravet
2021-01→2029-11·Not yet recruiting
NCT07546416
486 pts·MM
2025-01→TBD·Active
NCT05651482
1,151 pts·MM
2024-04→2025-02·Not yet recruiting
+1 more trial
4,402 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-02-171.1y agoPh3 Readout· MM
2029-11-093.6y awayPh3 Readout· Dravet
2031-09-165.5y awayPh3 Readout· MM
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Complet…
P3
Not yet…
P3
Not yet…
P3
Active
Catalysts
Ph3 Readout
2025-02-17 · 1.1y ago
MM
Ph3 Readout
2029-11-09 · 3.6y away
Dravet
Ph3 Readout
2031-09-16 · 5.5y away
MM
ActiveCompletedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03093432 | Phase 3 | Dravet | Not yet recr... | 91 | VA |
| NCT07546416 | Phase 3 | MM | Active | 486 | HAM-D |
| NCT05651482 | Phase 3 | MM | Not yet recr... | 1151 | SRI-4 |
| NCT07392521 | Phase 3 | MM | Completed | 2674 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| MRN-7409 | Moderna | NDA/BLA | SHP2 |